WO2024147073 - LIQUID ORAL FORMULATIONS OF NETUPITANT AND PALONOSETRON
National phase entry:
Publication Number
WO/2024/147073
Publication Date
11.07.2024
International Application No.
PCT/IB2023/063415
International Filing Date
31.12.2023
Title **
[English]
LIQUID ORAL FORMULATIONS OF NETUPITANT AND PALONOSETRON
[French]
FORMULATIONS ORALES LIQUIDES DE NÉTUPITANT ET DE PALONOSÉTRON
Applicants **
HELSINN HEALTHCARE SA
Inventors
PARISI, Davide
FRIZZARIN, Stefano
FABIANI, Flavio
Priority Data
63/436,713
03.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2849 | |
| EPO | Filing, Examination, Granting | 22982 | |
| Japan | Filing, Examination, Granting | 3076 | |
| South Korea | Filing, Examination, Granting | 4079 | |
| USA | Filing, Examination, Granting | 11540 |
Total:
44,526
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Orally administered liquid formulations of netupitant and palonosetron that are efficacious, chemically stable and physiologically balanced for safety and efficacy.[French]
Des formulations liquides administrées par voie orale de nétupitant et de palonosétron qui sont efficaces, chimiquement stables et physiologiquement équilibrées pour la sécurité et l'efficacité.